Skip to main content

Table 1 General characteristics and eye sign presentation of the two patient groups

From: Eye signs as a novel risk predictor in pulmonary arterial hypertension associated with systemic lupus erythematosus

 

Improved group (n = 12)

Non-improved group (n = 17)

P

Gender (F/M)

12 (100%)

16 (94.1%)/1(5.9%)

0.393

Age (years)

41.42 ± 10.10

38.41 ± 12.19

0.565

Functional level

  

0.006**

I

6 (50%)

0

 

II

4 (33.33%)

2 (11.76%)

 

III–IV

2 (16.67)

10 (58.82%)

 

NTproBNP

297 (135, 586)

1200 (688, 2155)

0.000*

6MWD (m)

420 (400, 470)

360 (300, 410)

0.018*

Medication

   

Corticosteroids

12 (100%)

17 (100%)

 

Endothelin inhibitors

4 (33.3%)

8 (47.1%)

0.460

PDE5 inhibitors

2 (16.7%)

3 (17.6%)

0.945

Combination therapy

6 (50%)

6 (35.3%)

0.428

eye signs

   

Ischemic areas, n (%)

6 (50%)

8 (47.1%)

0.876

Reticulum deformity,

n (%)

4 (33.3%)

6 (35.3%)

0.913

Microangioma, n (%)

6 (50%)

9 (52.9%)

0.876

Twisting, n (%)

11 (91.7%)

16 (94.7%)

0.798

Dilation, n (%)

7 (58.3%)

5 (29.4%)

0.119

Wound spot, n (%)

5 (41.7%)

13 (76.5%)

0.057

Hemorrhage, n (%)

3 (25%)

5 (29.4%)

0.793

blood vessel loss, n (%)

2 (16.7%)

5 (29.4%)

0.430

VD (n/mm2)

1.83 ± 0.79

0.98 ± 0.42

0.001**

MFI

2.4 (2.0, 2.87)

1.2 (1.0, 1.35)

0.002**

  1. 6MWD 6-minute walking distance; WHO FC World Health Organization functional class; NT-proBNP N-terminal prohormone of brain natriuretic peptide; VD vessel density; MFI microvascular flow index; *P < 0.05, **P < 0.01
Back to article page

Advances in Rheumatology

ISSN: 2523-3106